AstraZeneca’s Tagrisso plus chemo recommended for approval in EU

Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24

The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030

Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes

Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy

FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients

Central Council for Research in Ayurvedic Sciences launches ‘PRAGATI-2024’

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib